Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 126.04 USD 0.01%
Market Cap: 7.2B USD
Have any thoughts about
Ascendis Pharma A/S?
Write Note

Ascendis Pharma A/S
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ascendis Pharma A/S
Note Receivable Peer Comparison

Comparables:
GMAB
ZEAL
B
BAVA
F
FLUO
BIOPOR

Competitive Note Receivable Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Ascendis Pharma A/S
NASDAQ:ASND
Note Receivable
€2.2m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Note Receivable
kr77m
CAGR 3-Years
33%
CAGR 5-Years
46%
CAGR 10-Years
27%
Zealand Pharma A/S
CSE:ZEAL
Note Receivable
kr23.9m
CAGR 3-Years
166%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
Fluoguide AS
STO:FLUO
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Note Receivable
kr4.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Ascendis Pharma A/S's Note Receivable?
Note Receivable
2.2m EUR

Based on the financial report for Jun 30, 2024, Ascendis Pharma A/S's Note Receivable amounts to 2.2m EUR.

What is Ascendis Pharma A/S's Note Receivable growth rate?
Note Receivable CAGR 3Y
9%

Over the last year, the Note Receivable growth was 4%. The average annual Note Receivable growth rates for Ascendis Pharma A/S have been 9% over the past three years .

Back to Top